STOCK TITAN

Veradermics (MANE) director-linked trusts sell 100,000 shares of common stock

(Very High)
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Entities associated with Veradermics, Inc director John W. Childs reported selling a total of 100,000 shares of Veradermics common stock on August 12, 2026. The shares were held indirectly through the John W. Childs 2013 Revocable Trust and J.W. Childs Associates (FL), L.P., with prices based on weighted-average sale ranges.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider CHILDS JOHN W
Role Director
Sold 100,000 shs ($10.71M)
Type Security Shares Price Value
Sale Common Stock F1, F2 15,000 $106.14 $1.59M
Sale Common Stock F3, F2 80,000 $107.23 $8.58M
Sale Common Stock F2 5,000 $108.24 $541K
holding Common Stock F4 -- -- --
Holdings After Transaction: Common Stock — 2,102,006 shares (Indirect, See Footnote)
Footnotes (4)
  1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.77 to $106.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. F2. Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
  3. F3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.04 to $107.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4. Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
Shares sold (block 1) 15,000 shares at $106.14 per share Indirect sale of Veradermics common stock on 2026-08-12, weighted-average price
Shares sold (block 2) 80,000 shares at $107.23 per share Indirect sale of Veradermics common stock on 2026-08-12, weighted-average price
Shares sold (block 3) 5,000 shares at $108.24 per share Indirect sale of Veradermics common stock on 2026-08-12
Total shares sold 100,000 shares Aggregate non-derivative common stock sales reported for 2026-08-12
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect financial
"All reported sales were indirect. Shares were held by the John W. Childs 2013 Revocable Trust"
revocable trust financial
"Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
dispositive power financial
"may be deemed to hold voting and dispositive power with respect to these securities"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

FAQ

What insider transaction did Veradermics (MANE) report for John W. Childs?

Veradermics reported that entities associated with director John W. Childs sold 100,000 shares of common stock on August 12, 2026. The transactions were reported as indirect sales through a revocable trust and a limited partnership.

How many Veradermics (MANE) shares were sold and at what prices?

A total of 100,000 shares of Veradermics common stock were sold at weighted-average prices of $106.14, $107.23, and $108.24 per share. Each weighted-average price reflects multiple trades within specified price ranges.

Were the Veradermics (MANE) insider sales by John W. Childs direct or indirect?

All reported sales were indirect. Shares were held by the John W. Childs 2013 Revocable Trust and J.W. Childs Associates (FL), L.P., over which Childs, as trustee, may be deemed to have voting and dispositive power.

On what date did the Veradermics (MANE) insider transactions occur?

The reported insider transactions occurred on August 12, 2026. On that date, entities associated with director John W. Childs executed three separate indirect sales of Veradermics common stock at different weighted-average prices.

Were John W. Childs’ Veradermics (MANE) share sales under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes do not describe any trading plan. The sales are therefore not identified in the report as being executed pursuant to a Rule 10b5-1 trading arrangement.

Which entities linked to Veradermics (MANE) director John W. Childs held the sold shares?

Sold shares were held by the John W. Childs 2013 Revocable Trust and by J.W. Childs Associates (FL), L.P.. The trust is the sole owner of the partnership, and Childs, as trustee, may be deemed to have voting and dispositive power over these securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CHILDS JOHN W

(Last)(First)(Middle)
C/O VERADERMICS, INCORPORATED
470 JAMES ST.

(Street)
NEW HAVEN CONNECTICUT 06513

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/12/2026S15,000D$106.14(1)279,117ISee Footnote(2)
Common Stock08/12/2026S80,000D$107.23(3)199,117ISee Footnote(2)
Common Stock08/12/2026S5,000D$108.24194,117ISee Footnote(2)
Common Stock1,907,889ISee Footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.77 to $106.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2. Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.04 to $107.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
Remarks:
/s/ Michael Greco, Attorney-in-Fact08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)